AstraZeneca strikes licensing deal with RQ Bio for SARS-CoV-2 targeting mAbs
AstraZeneca has signed a licensing deal with RQ Biotechnology (RQ Bio) to gain access to a portfolio of early-stage monoclonal antibodies (mAbs) targeted against Covid-19 causing SARS-CoV-2 virus. As per the terms, AstraZeneca has acquired an exclusive global licence for developing, manufacturing, and commercializing mAbs against SARS-CoV-2. Iskra Reic — AstraZeneca Vaccines and Immune Therapies […]